NCT06907641View on ClinicalTrials.gov

Comparative Performance of 64Copper [64Cu]-SAR-bis-PSMA vs 68Ga PSMA-11 PET CT for the Detection of Prostate Cancer Recurrence in the Setting of Biochemical Failure Following Radical Prostatectomy

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Prostate Cancer (Post Prostatectomy)
Interventions
DRUG

64Cu-SAR-bisPSMA

All participants will receive a single administration of 200 MBq of 64Cu-SAR-bisPSMA

Trial Locations (1)

2010

RECRUITING

St Vincent's Hospital, Sydney, Darlinghurst

Sponsors
All Listed Sponsors
collaborator

Clarity Pharmaceuticals Ltd

INDUSTRY

lead

St Vincent's Hospital, Sydney

OTHER